-
Volume-for-price, including Pfizer Paxlovid in medical insurance negotiations/collective procurement can be a win-win situation
Time of Update: 2023-02-03
At present, there are only 2 small molecule drugs for new coronary pneumonia that have been marketed in China, including Azvudine of real biology and Paxlovid of Pfizer.
-
Shanghai Materia Medica: Medicinal and food cognate
Time of Update: 2023-01-04
In traditional medicine, the two elixirs of water and land are used to treat sperm loss and bring down; Yusuo Dan treatment of dream slippery essence; Distinguish clear pills to treat white turbidity.
-
A cancer treatment found naturally in tropical rainforest tree species
Time of Update: 2022-10-20
"essayPractical synthesis of the therapeutic leads tigilanol tiglate and its analogues Researchers at Stanford University have discovered a rapid, sustainable way to synthesize a promising cancer-fighting compound in the lab.
-
JAMA: Naproxen-acetaminophen-pantoprazole is used for pain management after arthroscopic bone surgery
Time of Update: 2022-10-12
Opioids are widely used for postoperative pain control after orthopedic surgery, and as of 2018, orthopedic surgeons are among the departments with the highest number of opioids in North America, and
-
The Lancet publishes a review article on neurofibromatosis research in China by Li Qingfeng's team from the Ninth Affiliated Hospital
Time of Update: 2022-09-07
In 2021, China's first expert consensus on clinical diagnosis and treatment of NF1 (2021), led by Professor Li Qingfeng from the Ninth Affiliated Hospital, with Associate Professor Wang Zhichao as the first author, and experts and scholars from multiple disciplines, will be published in the Chinese Journal of Rehabilitation and Reconstruction Surgery.
-
Cell Reports Yu Faxing's group reports on Hippo pathway cell surface regulatory elements and tumor targeted therapy strategies
Time of Update: 2022-09-06
On August 30, 2022, Faxing Yu's group from the Institute of Biomedical Sciences, Fudan University published a long article in Cell Reports entitled Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers research paper .
-
Prof. Zhitao Ying: The first guideline for CAR-T treatment of hematological malignancies was released, helping to guide the application of CAR-T in China
Time of Update: 2022-06-03
Indications Evaluation of peripheral blood mononuclear cells before treatment Bridging therapy collection of peripheral blood mononuclear cells Lymphocyte depletion before chemotherapy Check the lymphocyte depletion chemotherapy regimen before reinfusion Confirmation of patient status before reinfusion Approaches ICANN's recommended treatment approach For multiple myeloma and acute B lymphocytic leukemia, although no corresponding CAR-T products have been approved in China, the corresponding clinical research is progressing smoothly, so BCMA-targeted CAR-T is recommended for previous recipients.
-
The "Physician Law" has opened the legal floodgate for the implementation of off-label drug use today
Time of Update: 2022-05-02
The second paragraph of Article 29 of the "Physicians' Law" clearly stipulates that "in special circumstances such as no effective or better treatment methods, after obtaining the patient's explicit informed consent, the physician may use the drug instructions that are not specified but have evidence-based methods.
-
With these risk factors, family members of rigid patients should be careful
Time of Update: 2022-04-27
A study from Annals of Rheumatology followed up for 35 years and analyzed HLA-B27 levels, radiographic sacroiliitis status, clinical history including chronic inflammatory back pain (CIBP), acute anterior uveitis (AAU) and many other factors to predict its value for the development of axSpA .
-
Stroke: Prevention of morbidity and mortality after aneurysmal subarachnoid hemorrhage
Time of Update: 2022-04-24
CONCLUSIONS: Nimodipine and cilostazol may be the most effective treatments for preventing morbidity and mortality in patients with aneurysmal subarachnoid hemorrhage .
Nimodipine and cilostazol may be the most effective treatments for preventing morbidity and mortality in patients with aneurysmal subarachnoid hemorrhage .
-
The team of Professor Fang Wentao of the Affiliated Chest Hospital released the world's first postoperative recurrence prediction model for thymic tumors
Time of Update: 2022-04-18
Based on the analysis of the Chinese population for the first time, the research results put forward the world's first recurrence prediction model of thymic tumor and its significance for long-term management of prognosis, providing more powerful clinical guidance and management model for the management of thymic tumor patients in China and the world.
-
The 2nd China-made Wanbang Pharmaceutical "Insulin Lispro" was approved for listing
Time of Update: 2022-03-09
On January 26, NMPA issued an approval document showing that Wanbang Pharmaceutical's insulin lispro injection was approved for marketing, becoming the second domestic company .
Previously, only Lilly and Gan & Lee's insulin lispro were approved for marketing in China .
-
STAT3 protein degraders exhibit anticancer activity by increasing tumor sensitivity to PD-1 inhibitors
Time of Update: 2022-02-25
▲KTX-201 changes the tumor microenvironment (Image source: Kymera official website)Moreover, when KTX-201 was combined with an anti-PD-1 antibody, it resulted in a 60% complete remission in a mouse model of solid tumors, and the animals gained immune memory and the growth of re-implanted tumors was inhibited .
-
The first self-developed inflammatory immune drug
Time of Update: 2022-02-24
Article source: Medical Cube InfoAuthor: sunshineOn December 8, the CDE official website showed that the application for the clinical trial of BeiGene’s TYK2 allosteric inhibitor BGB-23339 was accepted .
-
In the controversial new drug for Alzheimer's disease, more than one-third of patients have cerebral edema after treatment
Time of Update: 2021-12-05
The paper reports on two large phase 3 clinical trials of aducanumab in the treatment of Alzheimer's disease, and focuses on the amyloid-related imaging abnormalities (ARIA) in patients during treatment .
